99 related articles for article (PubMed ID: 29504361)
21. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
Huang KH; Huang SF; Chen IH; Liao CT; Wang HM; Hsieh LL
Clin Cancer Res; 2009 Jun; 15(12):4174-80. PubMed ID: 19509163
[TBL] [Abstract][Full Text] [Related]
22. [The malignant potential of ovarian atypical endometriosis].
Guo L; Liu T; Lang J
Zhonghua Bing Li Xue Za Zhi; 2001 Jun; 30(3):169-72. PubMed ID: 11866970
[TBL] [Abstract][Full Text] [Related]
23. Hypermethylation of the PTEN gene in ovarian cancer cell lines.
Schöndorf T; Ebert MP; Hoffmann J; Becker M; Moser N; Pur S; Göhring UJ; Weisshaar MP
Cancer Lett; 2004 Apr; 207(2):215-20. PubMed ID: 15072831
[TBL] [Abstract][Full Text] [Related]
24. Distinct molecular pathways in ovarian endometrioid adenocarcinoma with concurrent endometriosis.
Zhang C; Wang X; Anaya Y; Parodi L; Cheng L; Anderson ML; Hawkins SM
Int J Cancer; 2018 Nov; 143(10):2505-2515. PubMed ID: 30152524
[TBL] [Abstract][Full Text] [Related]
25. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
[TBL] [Abstract][Full Text] [Related]
26. Promoter methylation status of
Atmaca HN; Gun S; Onal M; Tural S
Nucleosides Nucleotides Nucleic Acids; 2024 Jun; ():1-13. PubMed ID: 38830238
[TBL] [Abstract][Full Text] [Related]
27. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis.
Martini M; Ciccarone M; Garganese G; Maggiore C; Evangelista A; Rahimi S; Zannoni G; Vittori G; Larocca LM
Int J Cancer; 2002 Dec; 102(4):398-406. PubMed ID: 12402310
[TBL] [Abstract][Full Text] [Related]
28. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
29. Reactive oxygen species downregulate ARID1A expression via its promoter methylation during the pathogenesis of endometriosis.
Xie H; Chen P; Huang HW; Liu LP; Zhao F
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4509-4515. PubMed ID: 29131266
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
31. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
Zhang S; Wei L; Zhang A; Zhang L; Yu H
OMICS; 2009 Aug; 13(4):307-11. PubMed ID: 19645591
[TBL] [Abstract][Full Text] [Related]
32. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Verma M; Ebina Y; Nomura E; Yamamoto R; Sakuragi N; Dahiya R
Biochem Biophys Res Commun; 2004 Apr; 316(4):1156-62. PubMed ID: 15044106
[TBL] [Abstract][Full Text] [Related]
33. Absence of MGMT promoter methylation in endometrial cancer.
Rimel BJ; Huettner P; Powell MA; Mutch DG; Goodfellow PJ
Gynecol Oncol; 2009 Jan; 112(1):224-8. PubMed ID: 18973931
[TBL] [Abstract][Full Text] [Related]
34. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
35. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of the status of DACH1 gene promoter methylation in endometrial carcinoma and its clinical significance].
Deng XC; Li SR; Zhang Q; Zhou CJ; Yang QF; Jiang J; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):263-7. PubMed ID: 22781112
[TBL] [Abstract][Full Text] [Related]
37. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Abou-Zeid AA; Azzam AZ; Kamel NA
Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
[TBL] [Abstract][Full Text] [Related]
38. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
39. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
[TBL] [Abstract][Full Text] [Related]
40. COX-2 gene promoter DNA methylation status in eutopic and ectopic endometrium of Egyptian women with endometriosis.
Zidan HE; Rezk NA; Alnemr AA; Abd El Ghany AM
J Reprod Immunol; 2015 Nov; 112():63-7. PubMed ID: 26276091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
